{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:20:56Z","timestamp":1789536056304,"version":"build-2803163510"},"reference-count":12,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2007,1,31]],"date-time":"2007-01-31T00:00:00Z","timestamp":1170201600000},"content-version":"vor","delay-in-days":61,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2006,12]]},"abstract":"<jats:p><jats:bold><jats:sc>Abstract:\u2002<\/jats:sc><\/jats:bold>  <jats:bold>Bisphosphonates belong to a class of compounds similar to pyrophosphate. In these compounds the oxygen atom of the pyrophosphate is replaced by a carbon atom resulting in a P\u2010C\u2010P bond. They exert a potent inhibitory effect on osteoclasts and are therefore potent antiresorptive agents. They reduce bone turnover, increase bone mineral density, and decrease fracture risk both at the lumbar spine and the hip. Bisphosphonates have a high affinity for bone surfaces, where they accumulate, mainly at sites of bone remodeling. Due to their selectivity in action, they are usually not associated with systemic side effects. Their main unwanted effect is upper gastrointestinal irritation. Alendronate and risedronate are the two most widely used compounds in the treatment of postmenopausal osteoporosis. They are administered orally either daily or once weekly. Ibandronate is a highly potent newer third\u2010generation bisphosphonate administered once monthly with similar efficacy with respect to bone mineral density and fracture risk. Zoledronate, another potent third\u2010generation bisphosphonate, currently approved for the treatment of malignancy\u2010associated hypercalcemia, is currently undergoing phase III trials for the treatment of postmenopausal osteoporosis as an intravenous (i.v.) infusion once annually.<\/jats:bold> <\/jats:p>","DOI":"10.1196\/annals.1365.036","type":"journal-article","created":{"date-parts":[[2007,2,16]],"date-time":"2007-02-16T19:26:13Z","timestamp":1171653973000},"page":"397-402","source":"Crossref","is-referenced-by-count":58,"title":["Bisphosphonates"],"prefix":"10.1111","volume":"1092","author":[{"given":"IRENE","family":"LAMBRINOUDAKI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GEORGE","family":"CHRISTODOULAKOS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DIMITRIOS","family":"BOTSIS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,1,31]]},"reference":[{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.04.005"},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650140212"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199511303332201"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.11.6953"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030897"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.2.720"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.14.1344"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2006.01.161"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.040325"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.050313"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079904125003683"},{"key":"e_1_2_9_13_2","unstructured":"Black D.M. et al.2006.Effect of once\u2010yearly infusion of Zoledronic Acid 5 mg on spine and hip fracture reduction in postmenopausal women with osteoporosis: the HORIZON pivotal fracture trial.Presented at 28th annual meeting of the American Society for Bone and Mineral Research (ASBMR) 15\u201319 September. Philadelphia PA ."}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1196%2Fannals.1365.036","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1196\/annals.1365.036","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T21:45:15Z","timestamp":1695678315000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1196\/annals.1365.036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["10.1196\/annals.1365.036"],"URL":"https:\/\/doi.org\/10.1196\/annals.1365.036","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}